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Diffuse invasion of the brain, an intrinsic property of gliomas, renders these tumours incurable, and is a principal determinant of their
spatial and temporal growth. Knowledge of the invasive potential of gliomas is highly desired in order to understand their behaviour in
vivo. Comprehensive ex vivo invasion studies including tumours of different histological types and grades are however lacking, mostly
because reliable physiological invasion assays have been difficult to establish. Using an organotypic rodent brain slice assay, we
evaluated the invasiveness of 42 grade II–IV glioma biopsy specimens, and correlated it with the histological phenotype, the absence
or presence of deletions on chromosomes 1p and 19q assessed by fluorescent in situ hybridisation, and proliferation and apoptosis
indices assessed by immunocytochemistry. Oligodendroglial tumours with 1p/19q loss were less invasive than astrocytic tumours of
similar tumour grade. Correlation analysis of invasiveness cell proliferation and apoptosis further suggested that grade II–III
oligodendroglial tumours with 1p/19q loss grow in situ as relatively circumscribed compact masses in contrast to the more infiltrative
and more diffuse astrocytomas. Lower invasiveness may be an important characteristic of oligodendroglial tumours, adding to our
understanding of their more indolent clinical evolution and responsiveness to therapy.
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Diffuse gliomas are composed of cells of astrocytic and
oligodendrocytic phenotype (Louis et al, 2001). Accordingly, the
main types of diffuse gliomas (referred to hereafter as to ‘gliomas’)
are astrocytomas (As), oligodendrogliomas (Ols), and mixed
oligoastrocytomas (OlAs) (Kleihues et al, 2002). Malignancy of
gliomas is assessed by histological grades (II–IV) depending on
the presence of cellular pleomorphism, mitosis, vascular prolifera-
tion, and necrosis (Kleihues et al, 2002). The most malignant grade
IV tumours, multiform glioblastomas (GBMs), are associated with
a median survival of less than 12 months. Even grade II gliomas,
however, are ultimately lethal, because of relentless progression to
higher grade. Importantly, local treatments of tumours of all
grades fail because gliomas are highly invasive (Giese et al, 2003).
Thus, surgery fails since the tumour recurs inevitably at the
infiltrated margin, no matter how much margin has been resected
(Chicoine and Silbergeld, 1995; Silbergeld and Chicoine, 1997).
Since invasiveness is largely responsible for the dismal outcome
of glioma patients, its cellular and molecular mechanisms (Giese
et al, 2003) and kinetics (Burgess et al, 1997) have been intensively
studied. From a kinetic point of view, glioma invasion of the brain
is defined as a major determinant of glioma growth (Burgess et al,
1997; Swanson et al, 2000, 2002). Glioma growth involves two
independent determinants: infiltrative, resulting from tumour cell
spread in the brain parenchyma, and in situ proliferative, the net
result of cell division and apoptosis (Burgess et al, 1997).
Although highly desirable as a basis to assess the infiltrative
growth potential of glioma biopsies (Burgess et al, 1997), data on
glioma invasiveness in primary culture are scarce (for a review, see
De Bou ¨ard et al, 2002). This is particularly true for grade II and III
gliomas, of which less than 25 cases have been studied (De Bou ¨ard
et al, 2002). Results from these studies, obtained with different
invasion assays, are often contradictory. Moreover, it is now
admitted that some of these assays fail to mimic the in vivo
environment of gliomas, and probably provide biased estimates of
invasiveness (Jung et al, 2001; De Bou ¨ard et al, 2002). We
developed, on the basis of techniques recently described using
glioma cell lines (Jung et al, 2001; Murakami et al, 2001), an assay
wherein glioma biopsy fragments are implanted into rodent brain
slices (De Bou ¨ard et al, 2002). This organotypic assay, in which
invasive glioma cells show patterns of dissemination and
phenotypes similar to those in vivo, also allows studying
quantitatively the invasive potential of gliomas of different types
and grades.
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glioma biopsy specimens and explored by multivariate analysis
their relationships with established parameters of glioma prog-
nosis, such as histological type and grade, presence or absence of
deletions on chromosomes 1p and 19q (Louis et al, 2001), tumour
cell proliferation and apoptosis (Rhodes, 1998), vascularisation,
and cell density (McKeown and Ramsay, 1996). The main result of
this analysis is that Ols and mixed OlAs are less invasive than
purely astrocytic tumours of similar malignancy grade. In
Discussion, we offer a perspective on glioma invasion, emphasising
its interplay with in situ proliferation and the potential con-
sequences of this interplay for glioma growth.
MATERIAL AND METHODS
The analysis included biopsies from 51 patients (42 grade II–IV
gliomas, two grade I gangliogliomas, a choroid plexus papilloma,
two meningiomas, two squamous-cell lung carcinoma brain
metastases, and two gliosis specimens associated with primary
vasculitis of the brain and an arachnoid cyst). One biopsy fragment
was processed for cell culture as described below, and a second one
was submitted for histopathological analysis. Quantification of 1p/
19q status, histological features, cell proliferation, and apoptosis
was carried out on paraffin sections of the second fragment.
Histological classification of gliomas
Gliomas were classified by the guidelines of the WHO 2000
classification (Kleihues et al, 2002). Mixed OlAs were tumours in
which the two cell populations with oligo- and astroglial
phenotype were topographically separated, at least in some areas
(Bigner et al, 1999); this definition basically corresponds to the
biphasic OlAs in the WHO 2000 classification. Glioblastomas with
oligodendroglial component (GOCs) (Bigner et al, 1999; Kleihues
et al, 2002) were biphasic tumours with grade IV histological
features.
Slides were first examined separately by three pathologists (CC,
FC, and RG), and then in several sessions using a multi-head
microscope, until a consensus diagnosis was reached.
Immunohistochemistry
The following primary monoclonal (MC) and polyclonal (PC)
antibodies were applied (12–16h at 41C) to deparaffinised 5mm
sections of neutral formalin-fixed specimens, with or without
antigen retrieval (AR) (microwave treatment (3 5min) in citrate
buffer (pH 6.0)): anti-GFAP (PC, 1:100, Dako, Glostrup, Den-
mark), anti-Ki67 (MIB-1) (MC, 1:50, Immunotech, Marseilles,
France) (AR), anti-active human caspase 3 (PC, 1:2000, R & D
Systems, Abingdon, UK) (AR), and anti-CD34 (MC, 1:200)
(Dako). Bound primary antibodies were detected by a Vector Elite
ABC kit (Vector Laboratories, Burlingame, CA, USA) following the
manufacturer’s instructions with DAB as the chromogen and
haematoxylin counterstain. The anti-caspase 3 antibody was
detected by an FITC-conjugated secondary antibody (1:500,
Jackson ImmunoResearch, Philadelphia, PA, USA), and slides
were counterstained with DAPI (10mgml
 1). Negative controls had
the primary antibody omitted. In 13 cases, apoptosis was also
detected by an ApopTag
s kit (Intergen, Purchase, NY, USA)
according to the manufacturer’s instructions. Values of caspase 3
and ApopTag
s labeling indices (LIs), determined as outlined
below, were concordant (1.871.7 vs 1.971.6%) and tended to be
positively correlated (r¼0.56, P¼0.053). Owing to high varia-
bility of nuclear staining intensity with ApopTag
s (Rhodes, 1998),
the more easy-to-read caspase 3 immunolabelling was preferred
(Figure 1A, B).
Quantitative analysis of proliferation, apoptosis, and
histological features
All quantitative analyses were carried out using different modules
of the KS400 3.0 image analysis software (Zeiss, Germany) on
microscopic images digitised with a Coolsnap 300 camera (Roper
Scientific, Tucson, AZ, USA) coupled to an Axioplan 2 microscope
(Zeiss).
On histological sections, the Ki-67 (MIB-1) and active caspase
3 LIs (Schiffer et al, 2001), and tumour cell densities (cellsmm
 2)
were estimated in 10–15 microscopic fields ( 400) (at least 1000
tumour cells) in a representative tumour zone. The proliferation/
apoptosis (MIB1/caspase 3) ratios assessing the in situ growth
potential of a glioma (Rhodes, 1998) were calculated for 37
tumours. Vessel density was evaluated on CD34-immunostained
sections by image analysis (Guillamo et al, 2001). Compact
tumour areas (490% of tumour cells) and diffuse areas where
tumour cells intermingled with host cells were interactively
marked in the image graphics plane and their respective
proportions calculated.
Figure 1 Nuclear (A) and cytoplasmic (B) active caspase 3 immuno-
labellings. For the purposes of this illustration, bound anti-caspase 3 primary
antibody was detected by a biotinylated secondary antibody, an avidin–
peroxidase complex (both from Vector), and the TSA cyanine 3 signal
amplification system (PerkinElmert, Boston, USA). Separately acquired
images in the red and blue (DAPI) channels were subjected to a shading
correction by subtracting from the original image its version blurred by a
50-fold application of a 46-size lowpass filter, and mildly deconvoluted using
the iterative optical deconvolution module of KS400 3.0 with 10
itinerations of a maximum likelihood algorithm and suitable aperture
values. 1p/1c (C,D) and 19q (E,F) showing representative fields of
tumours without (C,E) and with (D,F) chromosomal losses. Note that, for
the simultaneous identification of two probes (e.g. 1p/1c), nine patterns of
labelling ranging from (0,0) to (2,2) are possible. All except (2,2) can be due
to nuclear truncation. We attempted to control for these inevitable
artefacts by applying the two methods outlined in Figure 2. To cut
cytoplasmic background staining and to safely overamplify probe signals,
FISH images represent field reconstructions of nuclei projected upon an
artificial black background.
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Dual-probe FISH on 5mm paraffin sections (39 gliomas and four
brain specimens free of tumour) was carried out with differentially
labelled probes for 1p36 (D1S32), centromere 1 (1c) (pUC1.77); all
specimens with 1p loss were subsequently tested with a locus-
specific probe for 19q13 (BAC2310A1). FISH was performed as
previously described with modifications (Van den Bent et al,
2003). Briefly, probes were nick-labelled with biotin-16-dUTP or
digoxigenin-11-dUTP (Roche Diagnostics, Almere, The Nether-
lands). Deparaffinised sections (4mm) were microwave-treated
(5min) in citrate buffer (pH 6.0), digested with pepsin solution
(Sigma) (0.005% in 0.1 M NaCl, pH 1.5) (20min) at 371C,
dehydrated in alcohols (70, 90, and 100%), and air-dried. The
probes were applied to the slides, and probes and specimen DNA
were simultaneously denatured at 801C (3min). Hybridisation was
carried out overnight (BAC2310A1) or over 48h (D1S32 and
pUC1.77). Following washes in 1.5 M urea/0.1 SSC at 451C
(15min) and in Tween 0.1%/2 SSC (5min), slides were exposed
to a FITC-conjugated sheep antibody (1:50) and Cy3-conjugated
avidin (1:100) (Roche Diagnostics) in PBS at 371C (20min),
washed twice in Tween 0.1%/2 SSC, counterstained with DAPI,
and mounted in antifade solution. Signals (60–100 nonoverlap-
ping nuclei per specimen) were counted on a Leica DM RXA
microscope equipped with single- or triple-pass filtres (DAPI/
FITC/Cy3) (Figure 1C-F). 1p/19q loss was evaluated by two
methods adapted to eliminate errors due to sectioning of nuclei.
The mean 1p/1c signal ratio (x1p/1c) of the nontumour specimens
was calculated. Tumours with ratios less than x1p/1c-3SD were
considered abnormal (Figure 2A). Additionally, for each specimen,
the cumulative counts of 1p and 1c (reference) signals were
compared by the Kolmogorov–Smirnov test (Figure 2B). These
two methods yielded identical results. To estimate 19q loss, for
which no reference probe was available, the cumulative signal
count of each tumour was compared with the mean cumulative
count of the nontumour specimens (Figure 2C).
In vitro invasion assay
The invasion assay was performed as previously described (De
Bou ¨ard et al, 2002). Briefly, 400mm coronal slices cut from the
brains of 7-days-old C57/bl6 mice were deposited onto Millicell-
CM membranes (Millipore, France) and maintained above 1ml of
medium (minimum essential medium (MEM) (Gibco, France),
1gl
 1 D-glucose, 10% foetal calf serum, 0.1gl
 1 transferrin,
16mgl
 1 putrescin, 40mgl
 1 N-selenium, 30mgl
 1 tri-iodothyr-
onin, 5mgl
 1 insulin, and 60mgl
 1 progesterone) in a standard
cell incubator. Fragments (0.1–0.4mm) containing histologically
verified viable tumour tissue were incubated in 30mgml
 1 DiI
(1,10-dioctadeccyl-3,3,30,30,-tetramethylindocarbocyanine perchlo-
rate) (Molecular Probes, Eugene, OR, USA) for 24h and implanted
in the thickness of the slice. A median of 10 (2–16) slice cultures
was studied per case. At 15 days post culture, slices were fixed in
4% paraformaldehyde (4h at 41C), removed from the filtre
membrane, and mounted in antifade medium Fluoromount G,
(Interchim, France). Animal studies were carried out in accordance
with institutional guidelines for the care, and in agreement with
the general recommmendations of the UKCCCR Guidelines for the
Welfare of Experimental Animals (1998).
Quantitative analysis of distance and cell density of
invasion
Distances of invasion of individual cells from the implant margin
(Figure 3) were measured in the point measurement mode of KS
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Figure 2 (A) 1p loss (1c: centromeric probe) in 39 gliomas: tumours with 1p/1c values below the mean–3s.d. threshold were considered to have 1p loss.
Tumours with ratios below this threshold not marked with an asterisk (*) also had 19q loss. 1p loss was detected in 12 out of 19 oligodendroglial and in one
out of 20 astrocytic tumours (Po0.0003); 1p/19q loss in nine out of 19 oligodendroglial and in zero out of 20 astrocytic tumours (Po0.0006). Four normal
brain specimens were used to calculate the threshold. An example of a grade II Ol with a 1p/19q loss estimated by comparison of 1p signals with 1c signals in
the same specimen (B), or of 19q signals with the mean 19q signal counts in the control group (C) (Kolmogorov–Smirnov test).
Figure 3 Examples of an invasive (A) and a practically noninvasive (B)
tumour in a brain slice. Each of the two image montages is composed of six
contiguous microscopic fields ( 100, 0.76mm
2). To avoid out-of-focus
fluorescent glow and to facilitate tumour cell recognition, each image of
glioma cells was separately segmented using grey morphology and adaptive
thresholding algorithms (KS400 3.0), and the resulting binary image was
overlaid in grey.
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y400 3.0. In each case, the maximal distance of invasion (D90) was
assessed by the 90th percentile calculated from the distribution of
all invasive cells (median n¼1923, range: 257–4766 for GBMs,
n¼396, range: 48–1215 for grade II and III gliomas).
The maximal cell density of invasion as a function of the
invasion distance (C90) was assessed by first calculating the 90th
percentile of the density of invading cell (cellsmm
 2) at every
100mm increment of migration distance. Then, C90 of each tumour
was calculated in arbitrary units (AU) as the area under the curve
of maximal cell densities of invasion. D90, assessing the outer
boundary of invasive cell spread, and C90, assessing the maximal
number of invading cells per unit area, are obviously two
complementary characteristics of invasion (Figure 4).
Statistics
Statistical analysis was performed using StatView F-4.11 (Abacus
Concepts, Berkeley, CA, USA) and GraphPad 3.00 (GraphPad
Software, San Diego, CA, USA). Two groups were compared by the
Mann–Whitney test and three groups by the Kruskall–Walis test.
Correlations were evaluated by the Spearman test (r), correlation
analysis (r), or the Fisher exact test. Principal component analysis
(PCA) was used to illustrate the relationship between invasion, 1p/
19q loss, in situ growth, and several quantitatively evaluated
histological features in grade II and III gliomas. Principal
component analysis summarises information contained in many
correlated variables as a few uncorrelated factors (principle
components), thus facilitating the comprehension of complex
relationships (McKeown and Ramsay, 1996). Using standard
techniques (StatView F-4.11), the number of factors extracted
was set to account for more than 80% of data variation and axes
were rotated by a Varimax/Orthotran transformation. Data in the
text are presented either as mean7standard deviation, or as
median (range).
RESULTS
Tumour histology and 1p/19q status
We examined 21 grade IV (14 purely astrocytic GBMs, six GOCs,
one giant-cell GBM) and 21 grade II and III gliomas (As: grade II,
n¼4, grade III, n¼4; Ols: grade II, n¼4, grade III, n¼6; OlAs:
grade II, n¼1, grade III, n¼2). FISH was successfully carried out
on 39 grade II–IV tumours. In these 39 tumours, and in the
subgroup of grade II and III tumours (n¼20), 1p loss (Po0.0003
and 0.008) and combined 1p/19q loss (Po0.006 and 0.007) were
strongly associated with oligodendroglial differentiation
(Figure 2A).
Invasion in relation to tumour phenotype
All gliomas showed variable numbers of invasive tumour cells
within the slice tissue (Figure 3). Specimens from tumours other
than gliomas were noninvasive in the slice assay.
Grade IV tumours showed higher D90 and higher C90 than grade
II and III tumours (Figure 5), mostly because of higher C90 values
(Figure 5B), since D90 values overlapped partially (Figure 5A).
When cases in the overlap zone in Figure 5A were separately
examined, grade IV (n¼12) still showed higher C90 than grade II
and III (n¼10) tumours: 94 (26–158) AUs vs 59 (19–121) AUs
(Po0.006). Grade II and grade III tumours were similarly invasive
(data not shown).
Within the group of grade II and III tumours, D90 and C90 were
lower for Ols and OlAs than for As (Figure 5C, D). Since
oligodendroglial differentiation was highly predictive of 1p or 1p/
19q loss, tumours harbouring these deletions also showed lower
D90 and C90 than nondeleted tumours (data not shown). Within the
group of grade IV tumours, C90 was lower for GOCs than for GBMs
(Figure 5F), while the difference in D90 was not significant
(Figure 5E).
This difference in C90 was largely due to different cell densities
of invasion within 0.5mm away from the implants. According to
C90 in this zone, tumours could be subdivided into three patterns
(Figure 4): high (200pC90p400cellsmm
 2) (nine GBMs); inter-
mediate (100pC90p200cellsmm
 2) (five GBMs, three GOCs), and
low (C90p100cellsmm
 2) (three GOCs and the giant cell GBM).
The giant cell GBM, an unusually indolent tumour, which has
not progressed for 2 years after biopsy and irradiation, was
minimally invasive (D90¼0.576mm; C90¼52AU) and was ex-
cluded from further analyses.
Invasion in relation to histological features and 1p/19q loss
in grade II and III gliomas
D90 was inversely correlated with 1p/19q loss (r¼ 0.64;
Po0.002), cell density (r¼ 0.66; Po0.0007), vessel density
(r¼ 0.49; Po0.03), and the MIB1/caspase 3 ratios (r¼ 0.45;
Po0.05), and positively correlated with proportion of diffuse areas
(r¼0.56; Po0.007). 1p/19q loss was positively correlated with cell
density and negatively with diffuse areas (Po0.03). Cell or vascular
density, and the MIB1/caspase 3 ratios were significantly positively
associated among themselves (0.43oro0.60), while the propor-
tion of diffuse areas was significantly negatively correlated with
cell density (r¼ 0.72), and the MIB1/caspase 3 ratios (r¼ 0.47).
A correlation matrix revealed correlations in 12 out of 15 pairs,
three factors were extracted that accounted for over 80% of the
variance, communality was 0.79–0.89, sampling adequacy was
78%, and factor structure simplicity was satisfactory. Factors
loadings (Table 1) translated into three patterns of growth:
‘vascular and in situ proliferative’ (factor 1), ‘hypercellular and
compact (not diffuse)’ (factor 2), and ‘noninvasive, characteristic
of tumours with 1p/19q loss (factor 3). Ols and OlAs had higher
factor scores than As for all the three factors (Figure 6). Thus,
correlation analysis of invasiveness, in situ growth, and histolo-
gical features suggests that grade II and III oligodendroglial
tumours with 1p/19q loss may tend to grow in situ as more
circumscribed and more vascular masses, in contrast to the more
diffuse, infiltrative, and less bulky As.
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Figure 4 Representative examples of the three patterns of maximal cell density of invasion (C90) in grade IV tumours: high (200pC90p400cellsmm
 2),
intermediate (100pC90p200cellsmm
 2), and low (C90p100cellsmm
 2) within 0.5mm from the implants. These three tumours showed comparable
maximal distance of invasion (D90), but important differences in C90: D90 and C90 are two complementary estimates of invasion.
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The ratio MIB-1/caspase 3 LI increased progressively with grade
(Figure 7A), and tended to be higher for Ols and GOCs than for
purely astrocytic tumours (Figure 7B). We examined this result in
32 additional grade II–IV gliomas selected from our files. Results
obtained in this expanded series (n¼69) confirmed that grade II
and grade III Ols had higher MIB-1/caspase 3 LIs ratios than As
(Figure 7C).
The MIB1/caspase 3 ratio (X), D90 (Y), and C90 (Z-axis) for each
tumour were plotted separately for grade II and III (Figure 7D) and
grade IV tumours (Figure 7E). This graphic analysis illustrated that
infiltrative spread is predominant in grade II and III As, while in
situ proliferation is predominant in Ols (Figure 7D). As
documented in other studies (Rhodes, 1998), some GBMs could
have very low proliferative potentials (Figure 7E), and presumably
grow predominantly by infiltration.
DISCUSSION
The main result of the present study is that oligodendroglial
tumours with 1p/19q loss were less invasive in vitro than
astrocytomas without deletions on these chromosomes. Correla-
tion analysis of parameters measured ex vivo suggested that in vivo
Ols may present relatively compact and hypercellular in situ
proliferating masses, in contrast to the more diffuse, less
proliferative, and more invasive As.
The ratio between cell spread and in situ proliferation is relevant
to describe how gliomas are organised in space (Swanson et al,
2000, 2002). Three patterns of glioma spatial organisation have
been defined: type I (solid bulk tumour), type II (solid tumour plus
a diffuse halo of infiltrating cells), and type III structures (diffuse
cloud of cells, no solid bulk) (Kelly et al, 1987). The different ratios
of infiltration and proliferation of grade II and III Ols and As
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Figure 5 D90 and C90 according to tumour grade (A,B) and tumour
type (C–F). D90 and C90 were lower for grade II and III than for grade IV
tumours (A,B), for grade II and III Ols than for grade II and III As (C,D);
grade IV GOCs had lower C90 than grade IV GBMs (F), but the difference
in D90 (E) was not significant (Mann–Whitney test).
Table 1 Factor loadings (only values b0.5 have been retained) resulting
from the principal component analysis
Factor 1 Factor 2 Factor 3
Vessel density +0.92 — —
Mib1/caspase 3 +0.75 — —
Diffuse areas —  0.89 —
Cell density — +0.87 —
D90 ——  0.74
1p/19q loss — — +0.91
Factor 1: vascular, in situ proliferative; Factor 2: hypercellular and compact (not
diffuse); Factor 3: noninvasive, characteristic of tumours with 1p/19q loss.
Vascular, in situ 
proliferative
Hypercellular, 
compact
Noninvasive, 
1p/19q loss
P < 0.04
P < 0.04
P < 0.04
Factor scores
5
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×
 
1
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Figure 6 Factor scores of grade II and III As and Ols for the principal
components extracted (Table 1): ‘vascular in situ proliferating’ (factor 1),
‘hypercellular and compact’ (factor 2), and ‘noninvasive, characteristic of
tumours with 1p/19q loss’ (factor 3). Score for all the three factors were
higher for Ols than for As (Mann–Whitney test).
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organisation of the less invasive Ols may correspond to type I or to
type II with a limited diffuse component, while that of the more
invasive As corresponds to more diffuse type II or to type III
structures.
The in vitro invasion assay correlates to a large extent with
aspects of glioma behaviour that are known to depend on the
degree of invasion. For instance, the time to tumour progression
after surgery (TTP) is thought to depend on the number of glioma
cells infiltrating the resected margin which, in order to form a
secondary growth, need to reach a critical cell density (Chicoine
and Silbergeld, 1995; Burgess et al, 1997; Silbergeld and Chicoine,
1997). An astrocytic (vs oligodendroglial or mixed) phenotype has
been found to be highly predictive of shorter TTP in 379 grade II
glioma patients (Karim et al, 1996). Up to four times longer TTP
was documented for 1p/19q codeleted Ols than for tumours
without these deletions (Fallon et al, 2004). Likewise, in a series of
pure GBMs and GOCs, 90% of the patients with unusually long
TTP had tumours with an oligodendroglial component (Kraus et al,
2000). Besides the numbers of invading cells, TTP could be
influenced by spatial patterns. Imaging methods detect tumour
bulks of a certain minimal cell density (the threshold cell density
concept) (Burgess et al, 1997; Swanson et al, 2000), and this bulk is
the target of surgery. The more compact and cellular the tumour
(e.g. type I), the greater the likelihood of a larger resection
(Swanson et al, 2002). Theoretically, tumour burden will remain
greater post-surgery for diffuse hypocellular tumours (e.g. type
III), since a smaller portion is identified and removed.
Patients with grade II and III Ols and OlAs have better prognosis
than patients with As of the corresponding grade even in the
absence of chemotherapy (Karim et al, 1996; Louis et al, 2001).
Similarly, in several studies gliomas with grade IV histology and an
oligodendroglial component have been associated with better
prognosis than pure GBMs (Donahue et al, 1997; Kraus et al,
2000). There is a seeming contradiction between this evidence and
results of comparative studies which have invariably documented
higher proliferation (Deckert et al, 1989; Karamitopoulou et al,
1994; Schiffer et al, 1995; Gordower et al, 1998; Heesters et al, 1999,
2002; Geiger et al, 2000) and lower apoptotic rates (Geiger et al,
2000; Heesters et al, 2002) for Ols than for As of similar grade. Our
results may help resolve this contradiction since models of glioma
growth kinetics predict that growth by infiltration should be faster
than growth by proliferation (Burgess et al, 1997). The opposition,
from a kinetic point of view, between infiltration and proliferation
may also have important biological underpinnings. There is
evidence that migrating cells do not proliferate (Giese et al,
1996) because they downregulate genes involved in cell prolifera-
tion (Mariani et al, 2001). The concomitant upregulation of
antiapoptotic programmes (Mariani et al, 2001; Joy et al, 2003)
indicates that these nondividing cells may also be longer-lived.
This particular kinetic profile of migrating cells should be taken
into account by models studying the relationships between the
infiltration and proliferation determinants of glioma growth.
The threshold cell density concept also explains why aggres-
siveness of gliomas should depend on high densities rather than on
long distances of cell invasion. Low-grade gliomas disseminate to
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Figure 7 MIB-1/caspase 3 ratios of gliomas of different grade (A) and type (B,C); three-dimensional plots – MIB-1/caspase 3 ratio (X), D90 (Y), C90 (Z-
axis) – of grade II and III tumours (D) and grade IV tumours (E). (A) In situ proliferation increased with grade; (B) higher in situ proliferation potentials for
Ols than for As and for GOCs than for GBMs were suggested for tumours studied in the invasion assay (Kruskal–Wallis test); (C) A larger series (n¼69)
confirmed that grade II and grade III Ols had higher MIB-1/caspase 3 ratios than As of the same grade (Mann–Whitney test); (D) factors that determine the
growth pattern of gliomas delineate important differences between the invasive As and the in situ proliferating Ols (grade II and III). (E) Note that some
GBMs have very low proliferative potentials, and presumably grow predominantly by infiltration: knowledge of the infiltrative potential of a glioma is probably
as important as knowledge of its capacity to proliferate.
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forming secondary structures such as perineuronal (satellitosis)
and subpial cell accumulations (Giese et al, 2003). If, however,
invasion is of low (i.e. subthreshold) cell density, it would not
result in clinical growth (Burgess et al, 1997). Indeed, D90 values
but not C90 values overlapped between grade IV and grade II and
III tumours.
The incidence of 1p/19q loss reported here is in keeping with
previous reports on GOCs (Kraus et al, 2001) and ‘classic’ Ols
showing cells with clear halos and typical branching vessels
(Sasaki et al, 2002, Watanabe et al, 2002) – 11 out of 13 grade II
and III Ols and OlAs in this series contained area with these well-
recognised features. 1p/19q codeleted classic Ols are associated
with long survival (Fallon et al, 2004) and tend to evolve
indolently even without treatment (van den Bent et al, 2003).
Although tentatively, we speculate that this particular evolution
may be due to limited infiltrative tumour growth. Ostensibly, the
high proportion of ‘classic’ Ols’ in our series calls for a
comparison with Ols devoid of classic features. We, however,
did not attempt to make this comparison, given the poor
consensus on the histological definition of these tumours, amply
illustrated in the recent literature (Fuller et al, 2003). Our results
support the view that ‘classic’ Ols’ may be a distinct glioma entity
characterised by high incidence of 1p/19q loss, limited invasive
potential, and the kinetic profile of in situ proliferating, relatively
circumscribed tumours.
In conclusion, we believe that our organotypic model of glioma
invasion is a realistic tool providing information about the
infiltrative potential of gliomas, a fundamental behavioural
characteristic of these tumours, which has been difficult to analyse
in quantitative terms.
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